Aimmune Therapeutics, maker of a peanut allergy treatment, said Monday that it will be acquired by the food conglomerate Nestle, which is seeking to expand its health sciences unit.
The all-cash deal values Aimmune at $2.6 billion, or $34.50 per share. Aimmune shares closed Friday at $12.60, near a four-year low due to the company’s struggles to launch its Palforzia peanut allergy treatment during the coronavirus pandemic.
About the Author Reprints
